#ONCY hashtag - Bluesky

#ONCY Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada Oncolytics Biotech (Nasdaq: ONCY) announced a proposal to change its jurisdiction of incorporation from Alberta, Canada, to the State of Nevada to align corporate domicile with its predominantly U.S.-based operations, management, shareholders, and capital markets activity. Effective January 1, 2026 the company became a domestic issuer under SEC rules and lost foreign private issuer status. The domestication requires shareholder approval at a Special Meeting on January 15, 2026 for holders of record as of December 9, 2025. A Form F-4 registration statement (No. 333-290954) has been declared effective by the SEC.

#ONCY Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer Oncolytics Biotech (Nasdaq: ONCY) reported clinical and translational data supporting pelareorep in second-line KRAS-mutant, microsatellite-stable metastatic colorectal cancer (mCRC).Key results: 33% objective response rate (ORR) in KRAS-mutant MSS patients versus historical 6–11% for bevacizumab+FOLFIRI, and reported >2x progression-free and overall survival versus bevacizumab+FOLFIRI. Translational analyses show increased KRAS-mutant–specific T cells. Company plans a sponsored controlled study to confirm findings.

#ONCY Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer

www.stocktitan.net/news/ONCY/oncolytics-bio...

1 0 0 0

StockTitan

@stocktitan.net

3 months ago

Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada The Special Meeting will be held to vote on, among other things, a series of transactions that will change the jurisdiction of Oncolytics from the Province of Alberta in Canada to the State of Nevada in the United States of America. In order to facilitate the Domestication, the Company expects to, prior to the Domestication, continue its existence from the...

#ONCY Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Oncolytics Biotech® Provides Update on Special Meeting of Shareholders Oncolytics Biotech (Nasdaq: ONCY) cancelled its previously scheduled Special Meeting of shareholders that had been set for December 15, 2025. The company said the meeting was postponed because of delays at the U.S. Securities and Exchange Commission caused by the recent federal government shutdown.When rescheduled, the Special Meeting will include a vote on a proposed domestication that would change Oncolytics’ jurisdiction from the Province of Alberta, Canada to the State of Nevada, USA. The company intends to set a new meeting date as soon as practicable.

#ONCY Oncolytics Biotech® Provides Update on Special Meeting of Shareholders

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer Oncolytics Biotech (Nasdaq: ONCY) announced FDA alignment on the Phase 3 pivotal study design for pelareorep in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).The trial will compare gemcitabine + nab-paclitaxel (GnP) alone versus GnP plus pelareorep, with an optional third arm adding a checkpoint inhibitor (CPI). The primary endpoint is overall survival; secondary endpoints include progression-free survival and objective response rate.The study is statistically powered to show a clinically meaningful survival benefit, may include an interim analysis to support accelerated registration, and is planned to launch in the first half of 2026. The protocol permits flexible CPI selection; pelareorep has previously been combined with atezolizumab, pembrolizumab, nivolumab, and retifanlimab in gastrointestinal and other tumor types.

#ONCY Oncolytics Biotech® Aligns with FDA on Pivotal Study Design for Pelareorep in First-Line Pancreatic Cancer

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada Oncolytics Biotech (NASDAQ: ONCY) filed a Form F-4 registration statement including a preliminary management circular/prospectus and announced a Special Meeting of Shareholders to vote on a continuance from Alberta to British Columbia and a domestication from British Columbia to Nevada. The Domestication requires an affirmative vote of not less than two-thirds of votes cast and is expected to occur on January 1, 2026 or as soon as practicable thereafter.The company said there are not expected to be material changes to operations or financial results, that it will continue SEC reporting and Nasdaq trading under ONCY, and that the move is intended to reduce regulatory burden and costs, aid capital raising, and reflect that most operations and shareholders are in the United States. Shareholders will also vote on a new incentive award plan.

#ONCY Oncolytics Biotech® Files Circular/Prospectus for Special Meeting of Shareholders To Change Jurisdiction of Incorporation to Nevada

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

6 months ago

33% Response Rate: Oncolytics' Cancer Drug Triples Standard Treatment Efficacy in Rare SCAC Cancer Trial Pelareorep achieves 33% ORR in SCAC cancer trial with 20 patients enrolled. Study expanding to US sites, including Northwestern University. Pancreatic cancer cohort shows 62% response rate.

#ONCY Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors Oncolytics Biotech (NASDAQ: ONCY) has released updated safety data for its immunotherapy drug pelareorep, showcasing favorable results across multiple gastrointestinal cancers. The analysis encompasses over 1,200 total patients, including more than 300 gastrointestinal cancer patients across 8 clinical studies.The data confirms pelareorep's consistent safety profile, with most adverse events being Grade 1 and 2, including fever, chills, fatigue, and gastrointestinal symptoms. The therapy has been tested in combination with various treatments, including modified FOLFIRINOX for metastatic pancreatic cancer, and in multiple tumor types such as colorectal and anal cancer.

#ONCY Oncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep Oncolytics Biotech (NASDAQ: ONCY) reported Q2 2025 financial results and outlined strategic plans for its immunotherapy drug pelareorep. The company reported a net loss of $6.2 million with $14.6 million in cash, projecting runway into Q1 2026.Key developments include plans for a registration-enabling pivotal study in first-line metastatic pancreatic cancer (mPDAC), with start-up activities expected in Q4 2025. Clinical data showed impressive 21.9% two-year survival rate in mPDAC patients compared to 9.2% historical benchmark. The company appointed new CEO Jared Kelly and CBO Andrew Aromando, both experienced in successful biotech transactions.Oncolytics demonstrated commitment to reducing dilution by terminating its At-the-Market and Equity Line of Credit facilities, and announced plans to delist from TSX while maintaining NASDAQ listing.

#ONCY Oncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Oncolytics Biotech Strategic TSX Exit: What Canadian Shareholders Need to Know About Nasdaq Trading Strategic TSX delisting supports U.S. market focus. Canadian shareholders can continue trading on Nasdaq. See how this corporate move impacts your investment.

#ONCY Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Oncolytics Fast-Tracks Revolutionary Pancreatic Cancer Drug Trial After FDA Green Light Fast Track-designated pelareorep advances toward registration trial for pancreatic cancer. FDA discussions signal potential accelerated pathway. Learn strategic timeline.

#ONCY Oncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential Oncolytics Biotech (NASDAQ: ONCY) hosted a key opinion leader (KOL) webinar focusing on pelareorep's clinical data in pancreatic and gastrointestinal cancers. The event highlighted significant survival benefits demonstrated by pelareorep-based combinations in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) patients.Key findings show that pelareorep combined with chemotherapy represents a promising treatment option for mPDAC patients. Translational data from multiple clinical trials validated pelareorep's mechanism of action, demonstrating tumor replication, chemokine expression stimulation, and correlation between tumor-infiltrating lymphocytes expansion and tumor size reduction.

#ONCY Key Opinion Leader Event Highlights Pelareorep's Compelling Pancreatic and Gastrointestinal Data And Future Potential

www.stocktitan.net/news/ONCY/key-opinion-le...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks overbought with declining relative strength, Mon Jul 21st - #GSIW #RILY #ONCY #INDI #INBX #FDUS #ENVX #BWEN #ZK - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Cancer Treatment Breakthrough: How This Drug Transforms Cold Tumors into Hot, Fighting Multiple Cancer Types New biomarker data reveals breakthrough cancer drug's success in resistant tumors. See how pelareorep activates immune response across multiple cancer types. Get insights.

#ONCY Oncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

8 months ago

Breakthrough Cancer Drug Doubles Survival Rate in Pancreatic Cancer, Shows Promise in Breast Cancer New clinical data reveals pelareorep's 21.9% survival rate in pancreatic cancer and 10+ month survival benefit in breast cancer. See complete trial results.

#ONCY Oncolytics Biotech® Highlights Transformative Pelareorep Survival Data in Multiple Tumors and Commitment to Registration-Enabling Studies

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Breakthrough Cancer Trial: Oncolytics Achieves 33% Response Rate in Anal Cancer, Reports Strong Q1 Progress Pelareorep shows promising 33% response rate in anal cancer trial, maintains $15.3M cash position. Multiple cancer trials advance with positive data. See full results.

#ONCY Oncolytics Biotech® Reports First Quarter Financial Results and Highlights Clinical Momentum

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Breakthrough Pancreatic Cancer Treatment Data: How Pelareorep Activates Immune System to Fight Tumors Latest ASCO study shows pelareorep's unique mechanism for activating immune responses in hard-to-treat pancreatic cancer. See groundbreaking results.

#ONCY Oncolytics Biotech® to Showcase New Pancreatic Cancer Data at ASCO Highlighting Pelareorep's Tumor-Fighting Mechanism of Action

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital SAN DIEGO and CALGARY, AB, April 10, 2025/ PRNewswire/-- Oncolytics Biotech ® Inc., a leading clinical-stage company specializing in immunotherapy for oncology, has entered into a share purchase agreement with Alumni Capital LP, an institutional investor. No offers or sales of common shares will be made in Canada or through the facilities of the TSX or any other...

#ONCY Oncolytics Biotech® Funds Pelareorep's Ongoing Clinical Development with a Share Purchase Agreement in Partnership with Alumni Capital

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Cancer Experts Reveal Promising Outlook for Revolutionary Immunotherapy Treatment Top oncology experts discuss pelareorep's breakthrough potential in breast and pancreatic cancers during prestigious H.C. Wainwright event. Full analysis inside.

#ONCY Oncolytics Biotech® and Pelareorep Discussed During Recent H.C. Wainwright Key Opinion Leader Event on Oncolytic Immunotherapies in Breast and Pancreatic Cancers

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks oversold with improving relative strength, Mon Apr 7th - #SPAI #STRO #ANRO #DDD #PET #ONCY #ISPR #BAER #GLSI - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can This Biotech's 33% Response Rate in Cancer Trials Transform Treatment? Pelareorep shows promising efficacy in breast, pancreatic, and anal cancer trials. Cash runway extends to Q3 2025 despite wider Q4 losses.

#ONCY Oncolytics Biotech® Reports Highlights and Financial Results for Q4 and Year-End 2024

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Can This Dual Cancer Trial Success Transform Oncolytics' Market Position? German regulatory clearance advances pancreatic cancer trial while anal cancer study shows superior response rates, positioning pelareorep for multiple indications

#ONCY Oncolytics Biotech® Advances Key Pancreatic and Anal Cancer Trials, Strengthening Pipeline in 2025

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Clinical Trial Success: Oncolytics' Cancer Drug Shows Superior Results in Two Major Cancer Types Oncolytics receives German approval for expanded pancreatic cancer trial, reports enhanced response rates in anal cancer study at ASCO GI 2025

#ONCY Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Clinical Breakthrough: Oncolytics' Cancer Drug Shows Remarkable Results in Three Major Cancer Types Oncolytics receives German approval for expanded pancreatic trial enrollment, reports enhanced response rates in anal cancer, advancing immunotherapy development

#ONCY Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Nasdaq Issues Warning: Oncolytics Biotech Faces Critical 6-Month Deadline to Avoid Delisting Oncolytics receives Nasdaq notification for trading below $1.00, granted 180-day grace period until August 2025 to regain compliance and maintain listing.

#ONCY Oncolytics Biotech® Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Oncolytics Biotech's Co-Founder CEO Exits: Critical Leadership Change Amid Cancer Drug Development Co-founder Matt Coffey departs as CEO after 25-year tenure, leaving pelareorep cancer therapy development under interim leadership as board launches CEO search.

#ONCY Oncolytics Biotech® Announces Matt Coffey, Ph.D. Will Not Return to CEO Role Following Medical Leave of Absence

www.stocktitan.net/news/ONCY/oncolytics-bio...

0 0 0 0